Lilly Stands By Experimental Diabetes Drug, Despite Questions About Data
This article was originally published in Pharmaceutical Approvals Monthly
Despite early evidence that one of its experimental diabetes drugs may cause higher heart and blood pressure rates, Eli Lilly remains adamant that development should continue
You may also be interested in...
Cost reduction plan is aimed at saving $1 billion by the end of 2010 ahead of the patent expiration of Zyprexa.
There will be winners and losers for the makers of type 2 diabetes drugs as doctors and patients absorb news of a potentially higher cancer risk for Sanofi-Aventis' long-acting insulin Lantus. Not surprisingly, Novo Nordisk is working hard to come out on top in any shakeout and held a recent presentation to make its case to investors
Redeeming a priority review voucher obtained by developing a drug for a tropical disease will cost companies $6.1 million in fiscal 2011